Progyny, Inc. (PGNY)
- Previous Close
33.06 - Open
33.07 - Bid 32.34 x 100
- Ask 32.41 x 100
- Day's Range
32.34 - 33.29 - 52 Week Range
29.44 - 44.95 - Volume
604,569 - Avg. Volume
840,625 - Market Cap (intraday)
3.114B - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
52.26 - EPS (TTM)
0.62 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.67
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
www.progyny.com563
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PGNY
Performance Overview: PGNY
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGNY
Valuation Measures
Market Cap
3.11B
Enterprise Value
2.76B
Trailing P/E
52.19
Forward P/E
45.66
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.99
Price/Book (mrq)
5.62
Enterprise Value/Revenue
2.53
Enterprise Value/EBITDA
42.79
Financial Highlights
Profitability and Income Statement
Profit Margin
5.70%
Return on Assets (ttm)
5.98%
Return on Equity (ttm)
13.34%
Revenue (ttm)
1.09B
Net Income Avi to Common (ttm)
62.04M
Diluted EPS (ttm)
0.62
Balance Sheet and Cash Flow
Total Cash (mrq)
371.09M
Total Debt/Equity (mrq)
3.50%
Levered Free Cash Flow (ttm)
160.84M
Research Analysis: PGNY
Company Insights: PGNY
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PGNY
PGNY: Rating decreased to a HOLD
PROGYNY INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetPGNY: Lowering target price to $46.00
PROGYNY INC has an Investment Rating of BUY; a target price of $46.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetPGNY: Raising target price to $48.00
PROGYNY INC has an Investment Rating of BUY; a target price of $48.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetPGNY: Rating increased to a BUY
PROGYNY INC has an Investment Rating of BUY; a target price of $38.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target